National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$39.00
add to cart

Rights & Permissions

topleft topright

Immunization Safety Review: Vaccines and Autism (2004)
Board on Health Promotion and Disease Prevention (HPDP)
Institute of Medicine (IOM)

Citation Manager

. "Appendix E: Summary of Public Submissions." Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press, 2004.

Please select a format:

BibTeX EndNote RefMan


Page
194
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Immunization Safety Review: Vaccines and Autism
  • Marjorie H. Monteleon (Maine DEP Dental Mercury Workgroup), 2004. Reference to the Immunization Safety review Committee Meeting 2/9/04.

  • National Autism Association: Folder with stories from the families of children with autism (sponsored by individual parents). We want you to know the truth…

  • Sylvia Nichols, 2004. Autism and Vaccinations.

  • Clarence W. Tiske, 2004. Autism meeting nine, sedation thimerosal.

  • Lauren Underwood, 2004. Immunization Safety Review.

  • Linda Weinmaster, 2004. IOM vaccines and autism public comment.

  • American Autism Assocation; Sponsored by parents of autistic children.

The committee also received several submissions from the public stating potential theories of how vaccines/thimerosal injure children/adults together with unpublished background information and critiques of data.

  • Catherine Boyle, 2004. Immunization Safety Review—vaccines and autism: what about mitochondrial disease underlying autism?

  • Amy Carson, Angela Medlin, Karey Williams (Moms Against Mercury), 2004. Removal of all Mercury Products in Vaccines.

  • Enayati, A. New Autism Data: Slight Decrease May Reflect Mercury Removal from Vaccines (Schafer Autism Report).

  • M.R. Geier, D.A. Geier. 2004. Important additional considerations for the IOM committee on thimerosal.

  • M.R. Geier, D.A. Geier. 2004. New Important Additional Considerations for the IOM committee on Thimerosal II and III.

  • M.R. Geier, D.A. Geier. 2004. VAERS Database Raw Data for Independent Methodology Verification.

  • M.R. Geier, D.A. Geier. 2004. VSD Raw Data: Thimerosal and Autism.

  • Elizabeth Mumper (Advocates for Children, Ltd.), 2004. Letter.

  • J.D. Nordin, M. Goodman, D.M. Smeltzer, E.P. Ehlinger, K. Kephart. 2004. Commentary on data presented by the Geiers at the thimerosal meeting.

  • Lyn Redwood (SafeMinds), 2004. IOM 2-04 RhoD comments.

  • Lyn Redwood (SafeMinds), 2004. IOM 5-04 Primate Study comments.

  • Lyn Redwood (SafeMinds). VSD Comments to IOM 02-16-04.

  • Glen F. Rall (Fox Chase Cancer Center), 2004. Letter.

3) UNPUBLISHED PAPERS

The committee received many unpublished papers to supplement published articles. These include:

  • S. Bernard (SafeMinds), 2004. Analysis of the Autism Registry Data Base in Response to the Hviid et al. Paper on Thimerosal in JAMA (October, 2003).

Page
194